Literature DB >> 8794989

Prediction of in-vivo blood level with controlled-release dosage forms. Effect of the gastrointestinal tract time.

I M Ouriemchi1, J M Vergnaud.   

Abstract

The process of in-vivo drug transfer is very complex in the case of oral dosage forms with controlled release. A numerical model taking all the known facts into account, including the release of the drug controlled by diffusion through the dosage form along the gastrointestinal tract, the kinetics of absorption in the blood compartment and the kinetics of elimination was constructed. Various parameters intervene in an important manner for a given drug: the size of the dosage form which is associated with the rate of release of the drug, and the dose frequency in multidosing. Some emphasis is placed upon the gastrointestinal tract time which appears to be the main and first parameter to be considered in preparing a dosage form.

Mesh:

Substances:

Year:  1996        PMID: 8794989     DOI: 10.1111/j.2042-7158.1996.tb05939.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

3.  Assessment of blood level with controlled-release dosage forms: effect of the rate constant of elimination of the drug.

Authors:  A Aïnaoui; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

4.  Assessment of antibiotic levels in lung tissue with erosion-controlled dosage forms.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.